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In Brief
The AAC and SCaMC are two major
nucleotide carriers responsible for
transporting ATP/ADP and metal-
complexed ATP/ADP across the
mitochondrial inner membrane. Run et al.
reveal key structural difference between
the two homologs, which explains
SCaMC’s higher selectivity for
transporting MgATP over ATP compared
with AAC.
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The mitochondrial matrix is the supplier of cellular
ATP. The short Ca2+-binding mitochondrial carrier
(SCaMC) is one of the two mitochondrial carriers
responsible for transporting ATP across the mito-
chondrial inner membrane. While the ADP/ATP car-
rier (AAC) accounts for the bulk ADP/ATP recycling
in the matrix, the function of SCaMC is important
for mitochondrial activities that depend on adenine
nucleotides, such as gluconeogenesis and mito-
chondrial biogenesis. A key difference between
SCaMC and AAC is that SCaMC selectively trans-
ports MgATP whereas AAC only transports free
nucleotides. Here, we use a combination of nuclear
magnetic resonance experiments and functional
mutagenesis to investigate the structural basis of
the MgATP selectivity in SCaMC. Our data revealed
an MgATP binding site inside the transporter cavity,
while identifying an aspartic acid residue that plays
an important role in the higher selectivity for MgATP
over free ATP.
INTRODUCTION
Mitochondria play vital roles in energy metabolism of the cells
and supply most of the ATP, the energy currency in life (Huss
and Kelly, 2005). Selective transport of ATP and ADP into and
out of the mitochondrial matrix is catalyzed by two nucleotide
carriers, which belong to the large family of mitochondrial car-
riers that transport various metabolites, nucleotides, and vita-
mins across the inner mitochondrial membrane. The ADP/ATP
carrier (AAC) is the major carrier that exports ATP out of the
matrix for energy consumption while importing ADP for the pro-
duction of new ATP by the ATP synthase (Fiore et al., 1998; Klin-
genberg, 2008). Functional defects of AAC can be detrimental.
For example, defective mutations in the AAC lead to the Sengers
syndrome (Palmieri, 2008). Another carrier that transports ATP is
the short Ca2+-binding mitochondrial carrier (SCaMC) (Chen,
2004; del Arco and Satrustegui, 2004; Fiermonte et al., 2004).
While AAC accounts for the bulk ADP/ATP recycling in the1394 Structure 23, 1394–1403, August 4, 2015 ª2015 Elsevier Ltd Almatrix, the transport activity of SCaMC is important for mito-
chondrial activities in the matrix that depend on adenine nucleo-
tides, such as gluconeogenesis and mitochondrial biogenesis
(Aprille, 1988; Pollak and Sutton, 1980; Satru´stegui et al., 2007;
Schild et al., 1999; Traba et al., 2012).
The transport properties of SCaMC, however, are very
different from those of the AAC. First, the transport activity of
SCaMC is Ca2+ dependent, i.e., SCaMC remains inactive unless
stimulated by a cytosolic Ca2+ signal (Nosek et al., 1990; Pollak
and Sutton, 1980). SCaMC adopts, in addition to the trans-
membrane domain (TMD) that is homologous to the AAC, an
extramembrane N-terminal domain (NTD) that contains four
EF-hand motifs in a calmodulin-like arrangement (Fiermonte
et al., 2004; Satru´stegui et al., 2007; Yang et al., 2014). Previous
structural and biochemistry data suggest a capping/uncapping
mechanism by which the apo NTD caps the TMD cavity from
the intermembrane space of mitochondria and blocks substrate
transport, whereas Ca2+ binding converts NTD to a self-seques-
tered form that uncaps the cavity (Cavero et al., 2005; Chen,
2004; Yang et al., 2014).
Another key difference between AAC and SCaMC is in the
substrate selectivity of the TMD. Unlike the AAC that selectively
transports free ADP or ATP (Nury et al., 2006), the TMD of
SCaMC (SCaMCTMD) transports MgATP in exchange for phos-
phate (Pi). It has been shown that the SCaMCTMD has much
higher selectivity for MgATP than for free ATP, although it can
also transport ATP (Austin and Aprille, 1984; Fiermonte et al.,
2004; Pollak and Sutton, 1980). Earlier in vivo studies in rat liver
mitochondria show that the ATP uptake can be enhanced in the
presence of Mg2+ and is significantly depressed in the absence
of Mg2+ (Austin and Aprille, 1984; Pollak and Sutton, 1980).
In vitro studies by reconstituting recombinant SCaMCs and
measuring the uptake of [14C]ADP or [33P]Pi into proteolipo-
somes have shown a greater activity for MgATP than ATP (Fier-
monte et al., 2004).
To date, the only high-resolution crystal structures of mito-
chondrial carriers are those of AAC in complex with the inhibitor
carboxyatractyloside (CATR) (Figure 1A) (Pebay-Peyroula et al.,
2003; Ruprecht et al., 2014). In addition to the AACs, the back-
bone structure of the Uncoupling Protein 2 (UCP2), another mito-
chondrial carrier, has been characterized using nuclearmagnetic
resonance (NMR) in the presence of guanosine diphosphate
(GDP) (Berardi et al., 2011). In the case of UCPs, GDP is not a
transporting substrate but rather an inhibitor that inhibits the fattyl rights reserved
Figure 1. NMR Characterization of the AAC-Homologous Domain of SCaMC
(A) The crystal structure of AAC in complex with the inhibitor CATR (PDB: 1OKC). CATR is shown as sticks and balls in red. AAC residues interacting with CATR are
shown as green sticks.
(B) Proposed ATP binding site in AAC based on functional mutagenesis. The ATP pyrophosphate binds to K22, R79, and R279 (green sticks).
(C) The 1H-15N TROSY-HSQC spectrum of 0.4 mM U-[15N, 13C, 2H]SCaMCTMD in the presence of 60 mM DPC recorded at 30
C and 600 MHz.
(D) Backbone assignments and secondary structures of SCaMCTMD. Alignment between AAC and SCaMCTMD is the same as in Figure S1. Secondary structures
of AAC are indicated as cylinders and labeled as H1–H6 (TM helices) and h1–h3 (amphipathic helices). The assigned residues of SCaMCTMD are indicated as ‘+.’
Helical regions predicted by the assigned chemical shifts (Talos+) (Shen et al., 2009) are indicated as ‘o.’
(E) Homology model of SCaMCTMD made using Modeller 9 based on the sequence alignment in (A) and the crystal structure of bovine AAC.acid flipping activity of UCPs (Berardi and Chou, 2014; Garlid
et al., 1996). UCP2 has 20% sequence identity with AAC,
and the NMR structure shows that UCP2 has overall architecture
very similar to that of AAC (Berardi et al., 2011). In both cases, the
structure features six severely kinked transmembrane (TM)
helices packed to form a barrel that is open to the intermem-
brane space. The structures also show three structurally similar
domains arranged in quasi 3-fold symmetry, with each domain
consisting of two TM helices and an amphipathic helix between
them on the matrix side.
Although there are no structures showing the binding of sub-
strate toAAC, possibly due toweak substrate binding and the dy-
namic nature of the uninhibited states of the carriers, extensive
mutagenesis data suggest that the binding residues are located
in the middle of the cavity including Lys22, Arg79, Arg279,
Gly182, Ile183, and Tyr186 (Kunji and Robinson, 2006; Nury
et al., 2006), among which the conserved Lys22, Arg79, and
Arg279 form salt bridges with phosphates of ATP (Figure 1B).Structure 23, 1394TheSCaMCTMD has 27%–30%sequence identitywith AAC (Fier-
monte et al., 2004) and is also expected to have architecture
similar to that of AAC. Moreover, these basic residues that have
been proposed to be involved in ADP/ATP binding in AAC are
also conserved among the SCaMC sources. The alignment of
the key basic residues between AAC and SCaMCTMD (Figure S1)
is consistentwith the observation that theSCaMCcan also trans-
port free ADP or ATP. However, there are no clues as to how
SCaMCTMD achieves strong selectivity for MgATP over free ATP.
In this study, we used a combination of NMR and functional
mutagenesis to investigate the binding of MgATP to the
SCaMCTMD. NMR measurements identified locations of specific
MgATP binding. Functional mutagenesis of the substrate bind-
ing sites observed by NMR further identified a key aspartic
acid residue inside the cavity that is critical for MgATP transport
and for the selectivity for MgATP over ATP. In addition to MgATP
binding, our NMR data also suggest that the SCaMCTMD is struc-
turally homologous to the AAC.–1403, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1395
Figure 2. Chemical Shift Perturbations
Induced by MgATP Binding
(A) MgATP titrations showing residue-specific and
concentration-dependent chemical shift changes.
The peaks are from 2D 1H-15N TROSY-HSQC
spectra recorded with a 0.4 mM U-[15N, 13C, 2H]
sample. The spectra were recorded in the pres-
ence of 0 mM (red), 4.8 mM (yellow), 9.1 mM
(green), 13.0 mM (blue), and 16.7 mM (purple)
MgATP.
(B) Plots of Ddcomb (defined in Equation 2) versus
MgATP concentration for residues D361 in (A).
(C and D) Comprehensive Ddcomb mapping onto
the homology model of SCaMCTMD using NMR
titration data obtained from 3D TROSY HNCO
spectra recorded at 600 MHz. Residues with
Ddcomb > 0.030 ppm are shown in red and those
with 0.015 < Ddcomb < 0.030 ppm are shown in
orange.
Arrows in (A) indicate the direction of resonance
movements upon addition of the substrate. Arrows
in (C) indicate the cavity-lining residues.RESULTS
The TM Domain of SCaMC Adopts a Structural Fold
Similar to that of AAC
We first established an NMR-amenable and functionally relevant
sample of SCaMCTMD for investigating substrate binding. The
TMD of human SCaMC (residues 186–477) was expressed in
Escherichia coli cells, reconstituted in dodecylphosphocholine
(DPC)micelles, andpurified byNi-NTA affinity and size-exclusion
chromatography (see Experimental Procedures). The final NMR
sample, which contains 0.4 mM SCaMCTMD, 60 mM DPC,
20 mM 2-(N-morpholino)ethanesulfonic acid (MES) (pH 6.5),
shows NMR spectra with good resolution and resonance homo-
geneity (Figure 1C). Using three pairs of triple-resonance experi-
ments and 3D double 15N-edited nuclear Overhauser effect
spectroscopy (NOESY), we could assign80% of the backbone
resonances of non-proline residues (Figure 1D). The majority
of the unassigned residues are in the region from Asn257 to
Phe289, possibly due to exchange broadening. The mitochon-
drial carrier proteins have intricate anduniquearrangement of he-
lical segments that features six long TM helices with short breaks
and three amphipathic helices (Berardi et al., 2011; Pebay-Peyr-
oula et al., 2003;Ruprecht et al., 2014; Sounier et al., 2015). Using
sequence alignment and the crystal structure of AAC, we gener-
ated a homology model of the SCaMCTMD using the program
Modeller 9 (Figure 1E) (Webb and Sali, 2014). It should be noted
that the original AAC structure was solved in the complex with
an inhibitor CATR (Pebay-Peyroula et al., 2003), so the structural
model may not accurately reflect that of the free SCaMCTMD.
Nonetheless, themodel provides astructural framework for eluci-
dating substrate binding of this MgATP carrier.
The SCaMCTMD Binds Specifically to MgATP and ATP
It has been reported that the substrates of SCaMC include
MgATP, ATP, ADP, AMP, and Pi (Aprille, 1988; Austin and Aprille,1396 Structure 23, 1394–1403, August 4, 2015 ª2015 Elsevier Ltd Al1984; del Arco and Satrustegui, 2004; Fiermonte et al., 2004;
Joyal and Aprille, 1992). We first performed NMR titration exper-
iments to characterize the interactions between SCaMCTMD and
substrates. Tomeasure substrate-induced chemical shift pertur-
bations, SCaMCTMD sample was titrated with MgATP or ATP as
well as free Mg2+ solubilized in the NMR buffer. TheMgATP titra-
tion showed residue-specific and concentration-dependent
chemical shift perturbations (Figures 2A, 2B, and S2). Moreover,
addition of free ATP to the sample induced chemical shift
changes similar to those induced by MgATP (Figure S2). This
result is consistent with previous functional measurement that
both MgATP and ATP are substrates of SCaMC (Austin and
Aprille, 1984; Fiermonte et al., 2004; Pollak and Sutton, 1980).
Although MgATP and ATP show specific binding, the Mg2+ ion
alone induces little chemical shift changes (Figure S2), which is
also consistent with the fact that Mg2+ alone is not a substrate
of SCaMC.
We further examined MgATP interaction by titrating a U-[15N,
13C, 2H] sample using the 3D transverse relaxation optimized
spectroscopy (TROSY) HNCO experiment. The chemical shift
changes induced by MgATP are located at multiple parts of
the protein. As expected from the general model that substrates
bind inside the cavity of mitochondrial carriers, several cavity-
lining residues show strong perturbations, including Ile220,
Gln223, Val224, Lys313, Ala317, Asp361, and Ala457 (Fig-
ure 2C). In addition to the cavity, however, we observed strong
chemical shift changes located both at the cytosol-facing
mouth of the cavity and on the matrix side of the carrier (Fig-
ure 2D). The perturbed residues near the cavity mouth include
the N-terminal residues (Glu188, Lys189, Lys190, and
Ser191), and Lys378 and Gln476. The perturbed residues on
the matrix side include residues of H1 and H3 near the matrix
end of the cavity and residues of the amphipathic helices h1
and h2. We note that the chemical shift change is potentially
complicated by the possible equilibrium exchange betweenl rights reserved
the presumed c and m states, i.e., the substrate may interact
with the two states differently.
Among the perturbed residues, Asp361 shows relatively fast
binding saturation. By comparing the MgATP titration data of
Asp361 with the simulated binding curves for 0.4 mM protein
concentration at different KD values, the apparent KD at
Asp361 is estimated to be between 1 and 2 mM (Figure S3).Direct Identification of Substrate Binding Sites Using
Paramagnetic Probe
Chemical shift perturbation is an indirect indication of substrate
binding because it could have arisen from substrate directly
and/or binding-induced conformational change. To directly
probe substrate binding sites of SCaMCTMD, we used Mn
2+, a
paramagnetic ion, to replace Mg2+. Mn2+ is similar to Mg2+; it
has often been used as an Mg2+ substituent in many Mg2+-
dependent enzymatic reactions (Cathala and Brunel, 1975;
Guth and Burris, 1983; Hsu and Berg, 1978; Ohshima et al.,
2008). Paramagnetic relaxation enhancements (PREs) have
been demonstrated to be very useful for investigatingmembrane
proteins (Barrett et al., 2012; Berardi and Chou, 2014; Zhang
et al., 2015). In this experiment, we used the 3D TROSY HNCO
experiment that correlates the chemical shifts of backbone 1H,
15N, and 13C nuclides to measure resonance broadening due
to the PRE induced by the Mn2+. Addition of 1.25 mM MnATP
to a 0.4 mM SCaMCTMD sample resulted in a wide range of reso-
nance broadening (Figure 3A). The intensity of some resonances
decreased by more than 70%. Most of these resonances are
located in the loop of the cytosol-facing side of the cavity and
on the amphipathic helices on thematrix side of SCaMCTMD (Fig-
ure 3B). Only a small fraction of the affected residues are in the
central cavity.
The divalent cations such as Mg2+ and Mn2+ are known to
interact with phospholipids and acidic residues, resulting in
nonspecific binding. To separate the specific from nonspecific
effects, we employed displacement titration, which involves first
broadening the protein NMR peaks by the paramagnetic MnATP
(1.25 mM) and then measuring specific recovery of the peaks
upon incremental addition of the non-paramagnetic MgATP. In
this case, the rapidly recovered peaks should in principle corre-
spond to regions where MgATP specifically competes off
MnATP and the rate of recovery should reflect the relative bind-
ing affinity at these sites. The intensity recovery can be described
mathematically as
DI=DImax
½MgATP
K0D + ½MgATP ; (Equation 1)
where DI is the intensity recovery at a given MgATP concentra-
tion, DImax represents the maximum intensity recovery, and K
0
D
denotes the apparent displacement constant. More specifically,
intensity recovery in the presence of MnATP is the difference be-
tween the normalized peak intensity at a given MgATP concen-
tration (I) and that at no MgATP (I0), where the normalized peak
intensity is defined as (peak height)/(reference peak height
without MnATP or MgATP). For each of the displacement titra-
tion points ranging from 0 to 22.2 mM of MgATP, a 3D TROSY
HNCO spectrum was recorded (Figure 3C) to measure peak
heights. The I versus [MgATP] data were then fit to Equation 1Structure 23, 1394to derive the K 0D and DImax of each of the assigned residues
(Table 1).
We found that only a small subset of the broadened peaks
recovered with a well-defined displacement saturation profile
(Figure 3D) that could be fitted to Equation 1. For example, the
peak for Gly359, which almost vanished in the presence of
MnATP, recovered rapidly upon addition of MgATP, whereas
the peak for Gly429, which was also significantly reduced to
40%, did not recover. Highlighting the residues that show
significant PRE (I0<0:3), significant peak intensity recovery
(DImax>0:3), and fast displacement (K
0
D<2:5 mM) (Table 1) in
the structural model of the SCaMCTMD reveals a cluster of resi-
dues. They include residues Gly359, Asp361, Leu362, and
Ala363 of H4, shown in Figure 3E and labeled as site I. In addition
to the above residues, which form the most obvious binding
patch inside the cavity, several residues in the loop between
H4 and H5, Asp374, Asn375, Phe376, and Ala377, at the mouth
of the cavity, also show low K0D values, labeled as site II (Fig-
ure 3E). The overall results obtained using the paramagnetic
probe suggest that the MgATP binding sites are in sites I and II
of the protein.
To exclude the possibility that the PREs were caused by Mn2+
instead of MnATP and that Mn2+ was displaced by Mg2+ rather
than MgATP, we also performed titration using Mn2+ and Mg2+.
In the presence of 1.25 mM Mn2+, there are PRE effects for a
few residues mainly located near the mouth of the cavity and
the matrix side. Among the resolved peaks, the height of 11
peaks decreased by more than 90%. However, adding
increasing amounts of Mg2+ did not result in peak intensity re-
covery (Figure S4), suggesting that the PREs from Mn2+ in these
cases are mostly due to nonspecific partitioning of the divalent
cations at the phospholipid headgroups. This negative control
is a further confirmation that the residues of sites I and II in Fig-
ure 3E are specific binding sites for MgATP.
The NMR-Derived Substrate Binding Site Is Critical for
MgATP Selectivity
Of the two binding sites observed by NMR, one is inside the cav-
ity, which is anticipated based on earlier functional data, and the
other is outside the cavity and unexpected. It is thus important to
examine whether the two binding sites are functionally relevant.
We developed a liposome-based transport assay for measuring
MgATP and ATP transport by SCaMCTMD (Figure 4A). In this
assay, the SCaMCTMD used for the NMR experiments is recon-
stituted into liposomes with Pi present in both internal and
external buffers. Substrate transport is initiated by the addition
of MgATP or ATP to the external solution, followed bymonitoring
the transporter-mediated influx of ATP or MgATP using the lucif-
erase reporter. It has been reported that SCaMC transports
MgATP much faster than ATP (Fiermonte et al., 2004; Nury
et al., 2006). Indeed, our liposome experiments show that in
the same time duration, the SCaMCTMD proteoliposome on
average transports two to five times as much MgATP as ATP
(Figures 4B and S5), and this result is consistent with previous re-
ports that SCaMC has a 2- to 3-fold higher selectivity for MgATP
over ATP (Austin and Aprille, 1984; Fiermonte et al., 2004; Pollak
and Sutton, 1980).
Having established a quantitative assay that recapitulates the
hallmark of SCaMC function, i.e., strong selectivity for MgATP–1403, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1397
Figure 3. Direct Identification of Substrate Binding Sites Using Paramagnetic Probe
(A) A region of 2D 1H-15N TROSY-HSQC spectra of SCaMCTMD showing PRE effects of MnATP. Left and right panels correspond to spectra recorded with a
0.4 mM protein sample in the absence and presence of 1.25 mM MnATP, respectively.
(B) Mapping of MnATP-induced PRE onto the SCaMCTMD model. Peak intensities decreased by more than 90% are shown in red and those decreased between
70% and 90% are shown in orange.
(C) The intensity recovery of broadened peaks by addition of MgATP. The first panel shows the same spectral region as the right panel in (A). Panels 2–6 are
spectra recorded at increasing concentrations of 4.5, 8.69, 12.5, 16.0, and 22.2 mM MgATP.
(D) Plots of PRE (normalized peak intensity) versus MgATP concentration for the residues labeled in (A). The peak intensity recovery data of only G359 and G439
could be fitted to the binding displacement equation (Equation 1).
(E) Mapping of significant PREs that could be specifically reduced by MgATP (I0<0:3; DImax>0:3 and K
0
D<2:5 mM) (shown in red) onto the SCaMCTMD model.
Red lines in (A) and (C) are indications of the location of peak G359.
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Table 1. MnATP-Induced PREs and Specific Displacement of
MnATP by MgATP
Residue I0
a DImax
b K0D (mM)c
Gly359 0.070 0.9630 1.4891
Asp361 0.044 0.5555 1.2311
Leu362 0.047 0.5515 0.4143
Ala363 0.115 0.5455 0.1985
Asp374 0.050 0.5898 1.3272
Asn375 0.036 0.5775 2.2822
Phe376 0.132 0.6129 0.3267
Ala377 0.169 0.5507 0.0498
aNormalized peak intensity in the presence of 1.25 mM MnATP without
MgATP.
bMaximum peak intensity recovery as MnATP is displaced with MgATP.
cApparent displacement constant in Equation 1.over ATP, we next used the assay to carry out functional muta-
genesis to examine whether newly identified residues play a
role in this unique functional property of SCaMCTMD. Since acidic
residues are known to interact with divalent cations, an obvious
suspect is Asp361, which is approximately at the center of site I
and is completely conserved throughout SCaMC. Another sus-
pect is Asp374, which is a part of site II, although this residue
is not well conserved in SCaMC. We tested the effect of single
mutations D361Y and D374A on the function of SCaMCTMD.
The Asp361 wasmutated to tyrosine because the corresponding
amino acid at this residue position in AAC is tyrosine.
The two single mutants were purified following the same pro-
tocol; their TROSY heteronuclear single-quantum coherence
(HSQC) spectra overlap very well except for modest chemical
shift changes around the mutated residues (Figure S6), indi-
cating that the mutations did not change the carrier conforma-
tion. The liposome assays were performed to measure the effect
of the mutations on the ratio of the rate of MgATP transport to
that of ATP transport. The D374A mutant shows a ratio similar
to that of the wild-type (WT) (Figure 4B; Table 2). The D361Ymu-
tation, however, dramatically reduced the selectivity for MgATP
over free ATP as the ratio decreased from 4.4 to 1.1 (Figure 4B;
Table 2). We note that the D361Y mutant still shows transport
activity for the free ATP similar to that of the D374A mutant
(Table 2), suggesting that the abilities of the two mutants to
transport nucleotides are similar. The major difference is the
large reduction in selectivity for MgATP.
To further test the direct role of Asp361 in MgATP binding, we
examined whether the single mutant D361A can still bindMgATP
using the MnATP/MgATP displacement method. Addition of
1.25 mM MnATP caused similar PRE for glycines 245, 429,
439, and 459, as in the WT, but the resonance of Gly359, which
showed 90% intensity reduction in the WT, decreased only by
30% and did not show peak intensity recovery when titrating
withMgATP (Figure S7). This result indicates that the D361Amu-
tation has essentially abrogated MgATP binding to site I.
DISCUSSION
The NMR titration and functional mutagenesis data revealed
Asp361 of site I as a key residue for the SCaMCTMD to achieveStructure 23, 13944-fold higher selectivity for MgATP over free ATP. Based on
the structural model of SCaMCTMD shown in Figure 3E, Asp361
is inside the polar cavity of the carrier and is slightly closer to the
cytoplasmic side than the matrix side. This model was built
based on the assumption that SCaMCTMD and AAC have similar
tertiary structures. We believe this to be a good assumption
for two reasons. First, among the mitochondrial carriers, the
SCaMCTMD is one of the closest sequence homologs of AAC
with30% sequence identity; it is also the closest functional ho-
molog of AAC, as it can transport ADP and ATP. Second, the
AAC has an intricate arrangement of helical segments. The fact
that the helical segments of the SCaMCTMD agree well with those
of AAC is an indication that its overall architecture is similar to
that of AAC. Another issue is that the AAC structure after which
the model was built is in the CATR-bound state, which repre-
sents a state in which the central cavity is accessible from the
intermembrane space or the cytosolic side (denoted as the c
state). According to previous functional studies, the AAC in iso-
lated mitochondria is predominantly in the c state even in the
absence of the inhibitor (Klingenberg, 2008). We therefore
believe that the SCaMCTMD model derived from the NMR data
and sequence alignment is a good model for guiding mutagen-
esis and elucidating substrate binding.
The MgATP binding site inside the cavity was identified
directly based on the PREs induced by the paramagneticMnATP
and reduced PREs due to displacement of MnATP by MgATP.
But when titrating the SCaMCTMD with MgATP, several residues
on the matrix side of the carrier, which did not show PRE recov-
ery, showed significant chemical shift changes. Specifically,
these residues belong to the matrix ends of H1 and H3 and
amphipathic helices h1 and h2. The global chemical shift pertur-
bation suggests that MgATP binding inside the cavity can
allosterically affect the conformation and/or dynamics of the
matrix part of the carrier. This type of allostery is possible for
the carriers because substrate binding should facilitate the
conformational switch from the c state described above to
the m state, in which the cavity is accessible from the matrix
side. In this case, the conformational switch should involve rear-
rangements of the amphipathic helices and opening of thematrix
side of the cavity.
The NMR measurements identified two major binding sites
for MgATP (Figure 3E). Site I, which is the higher-affinity site
(average K0D 830 mM), contains residues Gly359, Asp361,
Leu362, and Ala363, and is inside the polar cavity. The lower-
affinity site II (average K0D 1,000 mM) contains residues
Asp374, Asn375, Phe376, and Ala377, in a loop near the mouth
of the cavity. We emphasize that although our NMR titration data
provide evidence for these two sites, there could be other
unidentified sites involving residues whose resonances could
not be assigned. The majority of unassigned residues are
between Arg209 and Asp216 (the center of H1), Asn257 and
Phe289 of H2, and Phe305 and Met309 (the center of H3). The
residues of site I are highly conserved whereas the residues of
site II are not, suggesting that site I is the functionally important
one. Furthermore, our functional mutagenesis experiments
showed that mutating Asp361 of site I to tyrosine eliminates its
selectivity for MgATP over ATP, but introducing the D374A mu-
tation in site II does not significantly affect theMgATP selectivity.
Although Asp374 in site II appears to be less important, it could–1403, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1399
Figure 4. Effects of Mutating MgATP Bind-
ing Sites on MgATP Selectivity
(A) Schematic illustration of the liposome assay for
measuring SCaMCTMD transport of MgATP and
free ATP (details described in Experimental Pro-
cedures).
(B) Ratios of transport rate of MgATP to that of free
ATP for the WT SCaMCTMD and its D374A and
D361Y mutants. The transport rate is quantified
with the total ATP transported into the liposome in
5min. Error bars are ±1 SD values determined from
three repeat measurements.
Table 2. Transport Activities of WT SCaMCTMD and Its Mutants
ATP MgATP MgATP/ATP
Empty meana 15.5 335.2
SDb 7.91 13.94
WT mean 8,890.6 38,857.6 4.4
SD 257.85 775.39 0.06
D361Y mean 3,707.3 4,129.3 1.1
SD 22.93 69.56 0.01
D374A mean 4,585.6 13,145.6 2.9
SD 80.19 66.50 0.04
aMean value of three replicate measurements.
bSDs calculated from three replicate measurements.play a secondary role in recruiting the substrate to the trans-
porter via charge-charge interaction.
SCaMCTMD can transport MgATP whereas AAC cannot. Since
their structures are homologous, comparing the cavity-lining res-
idues between AAC and SCaMCTMD can thus provide insights as
to how Asp361 plays a critical role in introducing the MgATP
selectivity to SCaMCTMD. Previous studies suggest that the
ATP binding residues in AAC are located in themiddle of the cav-
ity including Lys22, Arg79, Arg279, Ile183, and Tyr186 (Kunji and
Robinson, 2006; Nury et al., 2006). These residues are also
conserved in SCaMCTMD as Arg209, Lys260, Lys453, Ile354,
and Tyr357, respectively (Figures 5A and 5B). Among these,
the conserved basic residues such as Lys22, Arg79, and
Arg279 in AAC have been proposed to form salt bridges with
pyrophosphates of ATP. We believe that the corresponding
basic residues Arg209, Lys260, and Lys453 allow SCaMCTMD
to bind and transport free ATP like AAC.
A major difference between SCaMCTMD and AAC is that the
Asp361 central to site I of SCaMCTMD is Tyr190 in AAC (Fig-
ure 5C), although the regions around the two residues are very
similar (e.g., the tyrosine three residues before and after
Asp361). Tyr186, Tyr190, and Tyr194 in AAC form a tyrosine
ladder, which has been proposed to play a role in substrate
recognition (Dehez et al., 2008; Nury et al., 2006; Pebay-Peyr-
oula et al., 2003). It is thus conceivable that the Asp361 in
SCaMCTMD has the effect of increasing affinity for MgATP at
this position because aspartic acid is often involved in binding
to divalent cations, i.e., Asp361 might coordinate Mg2+ together
with the phosphate groups of ATP as illustrated in Figure 5D.
Although there may be other structural features developed in
SCaMCTMD for selectively transporting MgATP, we believe that
not having an acidic residue at position 190 in AAC could partially
explain why AAC has low selectivity for MgATP.
In conclusion, we have identified an acidic residue inside the
cavity of the SCaMC carrier domain responsible for both MgATP
binding and the strong selectivity for MgATP over ATP. Mito-
chondrial carriers are relatively small solute transporters with
similar molecular architecture. It is remarkable that these similar
structures demonstrate exquisite selectivity for substrates with
subtle differences, and the selectivity of the metal-complexed
ATP by SCaMC is just one of the many examples in the large
family of mitochondrial carriers. Structural investigations to un-
derstand the mechanism of substrate selectivity have been
extremely challenging due to the weak substrate interactions.1400 Structure 23, 1394–1403, August 4, 2015 ª2015 Elsevier Ltd AlOur study demonstrates the versatile use of NMR-based titration
experiments in identifying residues involved in substrate-
transporter interactions. We believe that this approach, in
combination with functional mutagenesis, will be applicable to
many other transporters for investigating substrate binding and
selectivity.
EXPERIMENTAL PROCEDURES
Sample Preparation
A gene encoding residues 186–477 of human SCaMC with a C-terminal
6xHis-tag was cloned into pET21a expression vector. The plasmid contain-
ing the protein insertion was transformed into E. coli BL21 (DE3) (New
England Biolabs) expression strain. The cells were grown at 37C in
M9 minimal media until OD600 reached 0.7–0.8. Isopropyl b-D-1-thiogalacto-
pyranoside was then added to a final concentration 0.5 mM to induce the
protein expression. The cells were harvested after incubation at 37C for
3 hr and resuspended in 50 mM Tris-HCl (pH 8.0) and 200 mM NaCl. The
cells were disrupted by a homogenizer, followed by centrifugation at
40,000 3 g for 30 min at 4C to remove the supernatant. The SCaMCTMD-
containing inclusion bodies were collected and solubilized in 20 mM HEPES
(pH 7.5), 150 mM NaCl, 3 M GdHCl, 1% Triton X-100, and 5 mM b-mercap-
toethanol. The resulting solution was applied to an Ni-NTA column, and
subsequently refolded on column by exchanging the denaturing buffer
with buffer containing 6 mM DPC detergent. The refolded protein was then
passed through the Superdex-200 (GE healthcare) size-exclusion column
and eluted as monomers at molecular weight 75 kDa, which is consis-
tent with the total molecular weight of the complex (34 kDa SCaMCTMD
plus 40 kDa DPC micelle). A typical NMR sample consists of 0.4–1 mM
SCaMCTMD in the NMR buffer (20 mM MES, 60 mM DPC [pH 6.5]). The
mutants D361Y, D361A, and D374A were expressed, purified, and refolded
with the same procedure as for the WT.l rights reserved
Figure 5. AProposedModel ofMgATPBind-
ing to SCaMCTMD
(A and B) Comparison between the cavities of AAC
and SCaMCTMD showing their overall similarity, as
well as the difference between Y190 in AAC and
D361 in SCaMCTMD (highlighted in red).
(C) Sequence alignment between SCaMCTMD and
AAC in the region around D361 in SCaMCTMD and
Y190 in AAC, showing that these two regions
are conserved in SCaMC and AAC. Residues
strictly conserved in both AAC and SCaMCTMD are
indicated by asterisks and shaded in grey; partially
conserved residues are indicated by colons; and
much less conserved residues by dots; D361 in
SCaMCTMD and Y190 in AAC are indicated by red
arrowhead and highlighted in red.
(D) Proposed model illustrating how MgATP could
bind to SCaMCTMD. In this model, ATP (shown as
yellow sticks) interacts with the three basic resi-
dues as in AAC, and Mg2+ (shown as purple
sphere) is coordinated between D361 and the ATP
phosphate groups.NMR Resonance Assignment
All NMR experiments were conducted at 30C. Sequence-specific assignment
ofbackbone 1HN, 15N, 13Ca, 13Cb, and 13C0 resonanceswasaccomplishedusing
3D TROSY-based HNCA, HN(CO)CA, HNCACB, HN(CO)CACB, HN(CA)CO,
and HNCO experiments (Kay et al., 1989; Pervushin et al., 1997). In addition,
the assignments were validated using a 3D (HN, HN)-HSQC-NOESY-TROSY
spectrum with 15N, 15N, and 1HN evolution in the t1, t2, and t3 dimensions,
respectively, recorded with NOE mixing time of 250 ms. These experiments
were performed using a 0.8-mM U-[15N, 13C, 2H]SCaMCTMD sample at 30
C
on a 600-MHz Bruker spectrometer equipped with a cryogenic TXI probe.
The NMR spectra were processed using NMRPipe (Delaglio et al., 1995), and
analyzed using XEASY (Bartels et al., 1995) and CcpNmr (Vranken et al., 2005).
NMR-Based Titration Experiments
NMR titrations of 500 ml of 0.2mM [15N]SCaMCTMD sample with 100 ml MgATP,
ATP, and free Mg2+ stock solution (100 mM in NMR buffer) were performed at
303 K on a 14-T Bruker spectrometer operating at 599.702 and 60.774MHz for
1H and 15N, respectively. 3D TROSY HNCO spectra were acquired to follow
the chemical shift perturbations of MgATP during titrations. A series of 0-,
25-, 50-, 75-, and 100-ml MgATP/ATP/Mg2+ stock solutions (100 mM in NMR
buffer) were added to a 500-ml 0.4 mM U-[15N, 13C, 2H]SCaMCTMD sample.
At each substrate concentration point the 1HN, 15N, and 13C0 chemical shift
changes induced by substrate binding were processed by NMRPipe and
analyzed by CcpNmr. The combined chemical shift differences (Ddcomb)
were calculated for each residue using the formula (Schumann et al., 2007)
Ddicomb =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
uHDd
i
H
2
+

uNDd
i
N
2q
; (Equation 2)
where DdH and DdN are chemical shift perturbations (in ppm) with respect to
the 1H and 15N chemical shift, and uH = 1.00, and uN = 0.15 are normalization
factors.Structure 23, 1394–1403, August 4, 2015The same U-[15N, 13C, 2H]SCaMCTMD sample
described above was used for measuring
displacement of the paramagnetic MnATP by the
non-paramagnetic MgATP. The MnATP was first
added to the NMR sample to final concentration
of 1.25 mM. At this concentration, a subset of res-
onances was completely broadened in the 3D
TROSY HNCO spectra. The NMR sample with
1.25 mM MnATP was then titrated with increasing
amounts of MgATP using a 100-mMMgATP stock
solution in the NMR buffer. The 3D TROSY HNCOspectra were recorded on addition of 25, 50, 75, 100, and 150 ml of MgATP
stock. The peak heights at each MgATP concentration were determined using
the CcpNmr software to monitor the recovery of resonances as MnATP were
displaced by MgATP. A 0.5-mM 15N-labeled sample was used for measuring
displacement of the paramagnetic Mn2+ by the non-paramagnetic Mg2+. The
2D 1H-15N TROSY-HSQC spectra were recorded on addition of 1.25 mM
MnCl2 and 5, 10, 15, 20, and 30 mM MgCl2. The peaks heights at each
MnCl2 and MgCl2 concentration were also determined using the CcpNmr
software.
3D Structure Modeling
The 3D structural model of SCaMCTMD was built based on the sequence align-
ment shown in Figure 1D and the crystal structure of AAC (PDB: 1OKC) using
the program Modeller 9.
Proteoliposome Assay
Nucleotide transport activity of SCaMCTMD was measured using liposomes
consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dio-
leoyl-sn-glycero-3-phospho-(10-rac-glycerol) (DOPG), 1,2-dioleoyl-sn-glyc-
ero-3-phosphoethanolamine (DOPE), and 14:0 1,10,2,20-tetra-(9Z-octadece-
noyl) cardiolipin (CL). To reconstitute SCaMCTMD into liposomes, a lipid
solution with lipid composition of DOPC/DOPG/DOPE/CL = 20:5:1:1 (molar
ratio) was made by dissolving the lipids in buffer A (20 mM HEPES, 20 mM
phosphate buffer [pH 7.8], 100 mM NaCl) with 10% detergent (1:1 mass ratio
of decyl maltoside/octyl glucoside) to a total lipid concentration of 20 mg/ml.
A protein sample (0.5 mM SCaMCTMD) was mixed with the lipid solution at a
1:200 protein/lipid ratio and then diluted 20-fold with buffer A to a lipid concen-
tration of 1 mg/ml. Detergent removal was performed twice on a PD-10 desalt-
ing column pre-equilibrated with buffer A. The external and internal buffer was
the same for the proteoliposome and thus contained the same concentration
of Pi. The resulting proteoliposome was stable for 2 days at room temperature.ª2015 Elsevier Ltd All rights reserved 1401
Empty liposomes without the addition of protein were prepared in the same
way as for a negative control.
Tomeasure the translocation activity, ATP or MgATPwas dissolved in buffer
A and added into external buffer to a final concentration of 20 mM. Reactions
started upon the addition of substrate and terminated with an immediate
removal of external substrates after 5 min by passing through PD-10 desalting
columns pre-equilibrated with buffer B (20 mMHEPES [pH 7.8], 140 mMNaCl)
two times. The amount of ATP transported into proteoliposome was detected
by luciferase/luciferin ATP determinant assay (Invitrogen) as described by the
manual. In general, a standard reaction solution containing 1.25 mg/ml firefly
luciferase and 0.5mMD-luciferin wasmade. A 10-ml sample and 100 ml of stan-
dard reaction buffer was mixed in a white opaque 96-well microplate followed
by immediate detection of luminescence with a spectraMax M5 (Molecular
Devices).
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